Revvity, Inc. is a top healthcare solutions provider with a market cap of $10.6 billion. Analysts predict an adjusted earnings of $1.14 per share for the third quarter, down 10.9% from last year. In fiscal 2026, earnings are expected to jump 9.9% to $5.35 per share.

Despite better-than-expected results, RVTY stock prices dropped 8.3% after Q2 earnings release. Revenue grew 4.1% to $720.3 million, beating estimates by 1.3%. Adjusted EPS dipped 3.3% year-over-year to $1.18 but surpassed estimates by 3.5%.

Stock prices for RVTY have fallen 25.9% in the past 52 weeks, underperforming XLV’s 6.7% decline and $SPX’s 14.7% gains. The company expects pressure on margins and subdued organic revenue growth, leading to lowered full-year guidance, causing concern among investors.

Analysts are cautiously optimistic about Revvity’s stock, with a consensus “Moderate Buy” rating. Of 17 analysts covering the stock, nine rate it as a “Strong Buy,” one as a “Moderate Buy,” and seven as “Hold.” The mean price target of $111.93 suggests a 21.5% upside potential.

Read more at Yahoo Finance: Here’s What to Expect From Revvity’s Next Earnings Report